In a 3‑year‑old child with stage 4 high‑risk neuroblastoma that is MYCN‑amplified, has unfavorable histology, and metastatic disease, which treatment regimen represents the current standard first‑line approach?

Treatment of High-Risk MYCN-Amplified Stage 4 Neuroblastoma: MCQ

Question

A 3-year-old child presents with newly diagnosed stage 4 neuroblastoma. Biopsy confirms MYCN amplification and unfavorable histology. MIBG scan shows bone and bone marrow metastases. Which treatment regimen represents the current standard first-line approach?

A. 4-8 cycles of carboplatin, cyclophosphamide, doxorubicin, and etoposide followed by surgical resection

B. 5-cycle induction (topotecan/cyclophosphamide × 2 cycles, then cisplatin-based × 3 cycles), followed by tandem autologous stem cell transplant

C. Single autologous stem cell transplant with full-dose carboplatin/etoposide/melphalan (CEM)

D. Immediate surgical resection followed by 6 cycles of chemotherapy

E. Busulfan/melphalan conditioning with single transplant

---

Correct Answer: B

---

Explanation

The standard first-line treatment for high-risk MYCN-amplified stage 4 neuroblastoma is a 5-cycle induction regimen (ANBL12P1 or ANBL1531) followed by tandem autologous stem cell transplantation. 1, 2

Induction Chemotherapy

• ANBL12P1/ANBL1531 are the preferred Category 1 induction regimens consisting of:

  • Cycles 1-2: Topotecan + cyclophosphamide 1, 2
  • Cycles 3-5: Cisplatin combined with alkylator-intensive agents 2

• This 5-cycle approach achieves an 80% end-induction response rate (partial response or better), which is comparable to older 6-cycle regimens but with reduced nephrotoxic and cardiotoxic exposure 1, 2

• The ANBL0532 6-cycle regimen remains an acceptable alternative, though the panel prefers the shorter 5-cycle protocols given equivalent efficacy and lower toxicity 1

• Surgical resection is deferred until after several cycles of cytoreductive chemotherapy, not performed upfront, as these aggressive tumors are rarely resectable at diagnosis 1, 2

Consolidation Strategy

• Tandem autologous stem cell transplant is the Category 1 recommendation for most high-risk patients, including those with MYCN amplification 1, 2

• The ANBL0532 randomized phase 3 trial demonstrated 3-year EFS of 61.6% with tandem transplant versus 48.4% with single transplant (Level 1 evidence) 1, 2

• The tandem approach consists of:

  • First transplant: Thiotepa + cyclophosphamide 1, 2
  • Second transplant (6-10 weeks later): Dose-reduced carboplatin/etoposide/melphalan 1, 2

Why Other Options Are Incorrect

Option A describes intermediate-risk therapy (4-8 cycles of carboplatin/cyclophosphamide/doxorubicin/etoposide), which is inadequate for high-risk MYCN-amplified disease 2

Option C (single transplant with full-dose CEM) is reserved only for two specific favorable subgroups:

• Stage L2, age ≥18 months, unfavorable histology, MYCN non-amplified 1, 2
• Stage M, age 12 to <18 months, MYCN non-amplified with unfavorable features 1, 2

Neither applies to this MYCN-amplified patient.

Option D reverses the correct sequence—upfront resection is rarely feasible and not recommended; surgery follows cytoreductive chemotherapy 1, 2

Option E (busulfan/melphalan) is a European alternative that showed superior EFS to CEM in European trials, but its role in North American practice remains investigational; it is not the standard first-line approach 1, 2

Additional Management Considerations

• Full disease reassessment at end-induction is critical: Patients with partial response or better proceed to consolidation, while those with progressive disease should not undergo standard consolidation 1, 2

• Radiotherapy to the primary tumor (21.6 Gy) is administered after recovery from high-dose chemotherapy, with the goal of gross total resection (>90% tumor removal) when vital structures permit 1, 2

• MYCN-amplified tumors paradoxically show better primary tumor response to neoadjuvant chemotherapy (72% volume reduction) compared to non-amplified tumors (47%), though this does not translate to improved survival 3

• Current 5-year EFS for high-risk neuroblastoma is approximately 51% with multimodal therapy, underscoring the continued challenge of this disease 2